TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a clinical study of ytaa05 cell injection in the treatment of patients with recurrent
/ refractory acute myeloid leukemia.The purpose is to evaluate the safety and preliminary
efficacy of FLT3 car-t cells in patients with recurrent / refractory FLT3 positive acute
myeloid leukemia.#TAA05 cell injection is a T cell targeting FLT3 chimeric antigen receptor#